TPMT activity exhibits a monogenic co-dominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmalogic effecs of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduces the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting dosesof azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on www.cpicpgx.org) .
INTRODUCTION
This document is an update to the Clinical Implementation Consorium (CPIC) Guidelines for Thiopurine Methyltransferease Genotype and Thiopurine guideline updated last in April 2013. The guideline text, evidence table and recommendations have been updated to reflect any new evidence.
Specifically, this guideline adds a recommendation for NUDT15 genotype with minor changes to the TPMT recommendation. Although most of the dosing recommendations have been generated from clinical studies in just a few diseases, we have extrapolated recommended doses to all conditions, given the pharmacokinetic nature of the genotype/phenotype associations. CPIC guidelines are published and periodically updated on www.cpicpgx.org. Detailed guidelines for use of phenotypic tests (e.g. TPMT activity and thiopurine metabolite levels), as well as analyses of cost effectiveness, are beyond the scope of this document.
FOCUSED LITERATURE REVIEW
A systematic literature review focused on TPMT and NUDT15 genotypes and thiopurine use was conducted (details in Supplement). Definitive reviews (1-4) were relied upon to summarize much of the earlier literature.
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DRUGS: THIOPURINES Background
Three thiopurines are used clinically: azathioprine (a prodrug for mercaptopurine), mercaptopurine, and thioguanine. Although all three medications share many of the same pharmacologic effects, mercaptopurine and azathioprine are generally used for non-malignant immunologic disorders, mercaptopurine for lymphoid malignancies, and thioguanine for myeloid leukemias. Because azathioprine is a prodrug for mercaptopurine, the two drugs can be considered to have identical interactions with TPMT and NUDT15. Recommendations for individuals with variants in one or both of these genes will be addressed in detail in the following sections.
GENES: TPMT AND NUDT15

Background
TPMT. TPMT activity is inherited as a monogenic, autosomal co-dominant trait (Supplement, Figure S1 ). Three TPMT single nucleotide polymorphisms (SNPs), which result in unstable proteins and enhanced TPMT protein degradation (2, 3), account for over 90% of low activity phenotypes and are the most common inactivating alleles, and so genotyping tests including these three variants have a high likelihood of being informative for TPMT phenotype (5, 6). Complementary phenotype laboratory tests can be helpful adjuncts to genotyping tests (Supplement, Other Considerations) (7).
TPMT catabolizes mercaptopurine to an inactive methylmercaptopurine base, leaving less parent drug available for eventual anabolism to active thioguanine nucleotides (TGNs, Figure 1) . The secondary metabolite of mercaptopurine, thioinosine monophosphate (TIMP), is also a substrate for TPMT, and methylTIMP (and its further phosphorylated metabolites, methylmercaptopurine nucleotides or MeMPN) have pharmacologic activity (mostly immunosuppressive and hepatotoxic), inhibit de novo purine synthesis, and may contribute to some of the adverse effects of mercaptopurine, generally hepatotoxicity (2, 8, 9) . Individuals who inherit two loss-of-function TPMT alleles (homozygous or This article is protected by copyright. All rights reserved. compound heterozygous TPMT deficient individuals) are at very high risk for life-threatening myelosuppression, due to very high TGNs, if given conventional doses of mercaptopurine (or azathioprine). Despite having higher TGNs than wild-type patients, only about 30-60% of TPMT heterozygotes cannot tolerate full doses of mercaptopurine or azathioprine (8, 10, 11) . Good thiopurine tolerance in some heterozygotes may be because although they have higher TGNs than homozygous wild-type patients, they have lower concentrations (and thus fewer toxic effects) of the MeMPNs than do normal metabolizers, which may offset the toxic effects of having higher TGNs.
Thus, there is less of a consensus over how to dose azathioprine and mercaptopurine in patients who are heterozygous for TPMT compared to those that are homozygous, although they are at a higher risk for toxicity compared to patients carrying two normal function alleles (12).
Although there is lower affinity between thioguanine and TPMT than between mercaptopurine and TPMT, TPMT significantly affects thioguanine pharmacokinetics and its cytotoxic effects (12-16).
Thioguanine is directly metabolized by TPMT to inactive methylthioguanine base, leaving less drug available for anabolism by HPRT and other enzymes to active TGN metabolites. There is not an analogous secondary metabolite of thioguanine to undergo activation via TPMT (i.e. there are no methylTIMP or methylmercaptopurine nucleotides). As a result, patients receiving thioguanine are able to tolerate substantially higher TGN concentrations than do those receiving mercaptopurine or azathioprine (15). Within each TPMT phenotypic group, the initial recommended relative dosage decreases are similar for thioguanine, mercaptopurine, and azathioprine ( Table and Frequency Table) . The variant p.R139C has been studied most extensively in patients receiving thiopurine therapy, thus, providing the strongest evidence for clinical implementation. Subsequent studies reported additional variants, most of which are rare, and their associations with clinical thiopurine toxicity do not rise to clinical actionability at this point, even though some showed decreased NUDT15 activity in in vitro. For this reason, these variants (*4 to *9) are designated as unclear function but may be clarified as more data emerge.
Inherited TPMT deficiency is the primary genetic cause of thiopurine intolerance in Europeans and
Africans, whereas risk alleles in NUDT15 explain the majority of thiopurine-related myelosuppression in Asians and have been found in Hispanics.
Genetic Test Interpretation
Genetic testing analyzes the DNA sequence at specific SNP locations in the TPMT and NUDT15 genes (Supplement). Each named star (*) allele is defined by the genotype at one or more specific loci (TPMT Allele Definition Table ( This article is protected by copyright. All rights reserved.
NUDT15 phenotypes, based on the most common * allele diplotypes, and these assignments are used to link genotypes with thiopurine prescribing recommendations. Of note, the phenotype of "possible intermediate metabolizer" has been introduced to the this guideline to describe an individual carrying one uncertain/unknown function allele PLUS one known no function allele, as this individual should be treated with "at least" the same precautions as would apply to an intermediate metabolizer.
Although inactivating TPMT and NUDT15 alleles have been identified in multiple populations (TPMT Frequency Table ( 
Available Genetic Test Options
See Supplementary material and the Genetic Testing Registry (https://www.ncbi.nlm.nih.gov/gtr/) for more information on commercially available clinical testing options.
Incidental findings
There are no diseases or phenotypic traits that have been linked to variation in TPMT or NUDT15 in the absence of thiopurine treatment (2).
Linking genetic variability to variability in drug-related phenotypes
There is substantial evidence linking TPMT and NUDT15 genotype with phenotypic variability (see Table S1 ). Pre-emptive dose adjustments based on TPMT genotype have reduced thiopurine-induced adverse effects without compromising desired antitumor and immunosuppressive therapeutic effects in several clinical settings (Table S1) . Similarly, retrospective studies strongly indicate that patients with loss-of-function NUDT15 alleles are at excessive risk of thiopurine toxicity if the standard dose is administered. This body of evidence, rather than randomized clinical trials, provides the basis for most of the dosing recommendations in Tables 2 and 3. http://guide.medlive.cn/ This article is protected by copyright. All rights reserved.
Therapeutic Recommendations
Thiopurines are used to treat malignant and non-malignant conditions, and thus the approach to dosing adjustments and the propensity to initiate therapy at higher vs. lower starting doses based on TPMT/NUDT15 status may differ depending on the clinical indication.. Thiopurines have a unique role in the treatment of many malignancies. The "normal" starting doses of thiopurines are generally "high" because they have been derived from trials which have been heavily weighted by the ~90% of the population who are wild-type for TPMT and NUDT15 and receive maximal tolerable doses by the standards of anticancer treatment (hence, full doses should be given to those who are normal metabolizers for TPMT and NUDT15, Tables 2 and 3). Because the level of thiopurine tolerance is highly correlated with genetic ancestry (17), the "normal" starting doses can also vary by geographic regions and clinical practice.
TPMT recommendation. If starting doses are already high (e.g., 75 mg/m 2 of mercaptopurine), as is true in some ALL treatment regimens, lower than normal starting doses should be considered in TPMT intermediate metabolizers (11, 15, 24, 25) and markedly reduced doses (10-fold reduction) should be used in TPMT poor metabolizers (26) ( Table 2) . This approach has decreased the risk of acute toxicity without compromising relapse rate in ALL (27) . Even at these markedly reduced dosages, erythrocyte TGN concentrations in TPMT poor metabolizers remain well above those tolerated and achieved by the majority of patients (who are TPMT normal metabolizers) (4, 26).
In some nonmalignant conditions, alternative agents may be chosen for TPMT intermediate or poor This article is protected by copyright. All rights reserved.
Some of the clinical data upon which dosing recommendations are based ( TPMT and NUDT15 recommendation. 
Recommendations for Incidental Findings
Not applicable. 
Other considerations
POTENTIAL BENEFITS AND RISKS FOR THE PATIENT
The benefits of pre-emptive TPMT testing are that doses that are customized based on TPMT status reduce the likelihood of acute myelosuppression without compromising disease control (4, 8, 24, 25) .
The risks would be that a proportion of TPMT intermediate metabolizers may spend a period of time at lower thiopurine doses than they can eventually tolerate, because only ~30-60% of TPMT heterozygous patients receiving conventional thiopurine doses experience severe myelosuppression (4, 8, 11) . However, because steady state is reached in 2-4 weeks, any period of "under-dosing"
should be short, and using this approach, at least in ALL and in inflammatory bowel disease, outcomes were not compromised (4, 8, 24, 25, 28 ).
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Similar benefits are expected with pre-emptive NUDT15 genotyping, especially for Asian patients,
given that these variants have comparable effects as risk alleles in TPMT. At least in ALL, leukemia cells with loss-of-function NUDT15 alleles are also more sensitive to mercaptopurine (20) and thus in theory NUDT15 genotyped guided dosing would not compromise anti-leukemic efficacy of this drug.
A possible risk to the patient is an error in genotyping (4). Some TPMT and/or NUDT15 variants may not be included in the genotype test used and patients with these variants may be assigned a "wildtype" (*1) genotype by default. Thus, an assigned "wild-type" allele could potentially harbor a no or decreased function variant. Because genotypes are life-long test results, any such error could stay in the medical record for the life of the patient.
CAVEATS: APPROPRIATE USE AND/OR POTENTIAL MISUSE OF GENETIC TESTS
Most of the time, thiopurines are given orally daily for a period of at least several months. Genotypebased starting doses are just that-starting doses, and in most diseases, titration to the desired degree (or lack thereof) of myelosuppression is required. Thus, clinicians must continue to evaluate markers of disease progression and/or of myelosuppression to adjust thiopurine doses up or down from the genotype-directed starting doses. One caveat is that some serious long-term adverse effects (secondary tumors) have been associated with defective TPMT activity without necessarily causing serious acute myelosuppression; whether capping doses of thiopurines in those with a TPMT defect will decrease the risk of the late effect of secondary cancer is not known. Some adverse reactions to thiopurines, such as pancreatitis and hepatotoxicity, are not related to low TPMT activity.
The discovery and clinical implementation of NUDT15 variants in thiopurine dosing is relatively recent and the exact impact of NUDT15 genotype-guided dose adjustments on toxicity and efficacy are less clear compared to TPMT.
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